BR112022025217A2 - Nanopartículas lipídicas - Google Patents
Nanopartículas lipídicasInfo
- Publication number
- BR112022025217A2 BR112022025217A2 BR112022025217A BR112022025217A BR112022025217A2 BR 112022025217 A2 BR112022025217 A2 BR 112022025217A2 BR 112022025217 A BR112022025217 A BR 112022025217A BR 112022025217 A BR112022025217 A BR 112022025217A BR 112022025217 A2 BR112022025217 A2 BR 112022025217A2
- Authority
- BR
- Brazil
- Prior art keywords
- lipid
- lnps
- present
- lipid nanoparticles
- specifically
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 6
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930182558 Sterol Natural products 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
NANOPARTÍCULAS LIPÍDICAS. A presente invenção refere-se ao campo de nanopartículas lipídicas (LNP); mais especificamente compreendendo um lipídio ionizável, um fosfolipídio, um esterol, um lipídio PEG e um ou mais ácidos nucleicos. As LNPs da presente invenção são caracterizadas por compreender menos de cerca de 1 % em mol de um lipídio C14-PEG2000; bem como percentagens particulares dos outros lipídios. A presente invenção fornece o uso de LNPs para administração imunogênica de moléculas de ácido nucleico, especificamente mRNA; tornando-os assim altamente adequados para uso em vacinas, como para o tratamento de câncer ou doenças infecciosas. Finalmente, são fornecidos métodos para preparar tais LNPs.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20179435 | 2020-06-11 | ||
EP21160384 | 2021-03-03 | ||
PCT/EP2021/065856 WO2021250263A1 (en) | 2020-06-11 | 2021-06-11 | Lipid nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022025217A2 true BR112022025217A2 (pt) | 2023-01-03 |
Family
ID=76355521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022025217A BR112022025217A2 (pt) | 2020-06-11 | 2021-06-11 | Nanopartículas lipídicas |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4164596A1 (pt) |
JP (1) | JP2023545886A (pt) |
KR (1) | KR20230050313A (pt) |
CN (1) | CN116133640A (pt) |
AU (1) | AU2021286911A1 (pt) |
BR (1) | BR112022025217A2 (pt) |
CA (1) | CA3186776A1 (pt) |
IL (1) | IL298765A (pt) |
MX (1) | MX2022015690A (pt) |
WO (1) | WO2021250263A1 (pt) |
ZA (1) | ZA202300131B (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023220746A1 (en) * | 2022-05-13 | 2023-11-16 | Corner Therapeutics, Inc. | Mrna encoding a constitutively-active cyclic gmp-amp synthase and lipid delivery vehicles for same |
CN114869859A (zh) * | 2022-06-02 | 2022-08-09 | 深圳厚存纳米药业有限公司 | 一种核酸纳米粒复合物及其制备方法 |
CN115998714B (zh) * | 2023-03-20 | 2023-06-30 | 威瑞生物科技(昆明)有限责任公司 | 一种脂质纳米颗粒、递送系统及递送系统的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2795110T3 (es) * | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
EP3060671B1 (en) * | 2013-10-22 | 2021-12-29 | Translate Bio, Inc. | Cns delivery of mrna and uses thereof |
ES2908268T3 (es) | 2013-11-12 | 2022-04-28 | Univ Brussel Vrije | Vector de transcripción de ARN y sus usos |
US20180085474A1 (en) * | 2015-01-23 | 2018-03-29 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
JP7333563B2 (ja) * | 2018-01-18 | 2023-08-25 | イーザアールエヌーエー イムノセラピーズ エンヴェー | 脂質ナノ粒子 |
-
2021
- 2021-06-11 KR KR1020237001212A patent/KR20230050313A/ko active Search and Examination
- 2021-06-11 AU AU2021286911A patent/AU2021286911A1/en active Pending
- 2021-06-11 BR BR112022025217A patent/BR112022025217A2/pt unknown
- 2021-06-11 CN CN202180049369.XA patent/CN116133640A/zh active Pending
- 2021-06-11 CA CA3186776A patent/CA3186776A1/en active Pending
- 2021-06-11 EP EP21731190.1A patent/EP4164596A1/en active Pending
- 2021-06-11 MX MX2022015690A patent/MX2022015690A/es unknown
- 2021-06-11 IL IL298765A patent/IL298765A/en unknown
- 2021-06-11 WO PCT/EP2021/065856 patent/WO2021250263A1/en unknown
- 2021-06-11 JP JP2022575923A patent/JP2023545886A/ja active Pending
-
2023
- 2023-01-03 ZA ZA2023/00131A patent/ZA202300131B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA202300131B (en) | 2023-10-25 |
IL298765A (en) | 2023-02-01 |
KR20230050313A (ko) | 2023-04-14 |
JP2023545886A (ja) | 2023-11-01 |
WO2021250263A1 (en) | 2021-12-16 |
CN116133640A (zh) | 2023-05-16 |
EP4164596A1 (en) | 2023-04-19 |
MX2022015690A (es) | 2023-02-22 |
AU2021286911A1 (en) | 2023-02-09 |
CA3186776A1 (en) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022025217A2 (pt) | Nanopartículas lipídicas | |
MX2022009018A (es) | Nanoparticulas lipidas. | |
Gote et al. | A comprehensive review of mRNA vaccines | |
Aldosari et al. | Lipid nanoparticles as delivery systems for RNA-based vaccines | |
Zhang et al. | Modification of lipid-based nanoparticles: An efficient delivery system for nucleic acid-based immunotherapy | |
EP3239132B1 (en) | Cationic lipid | |
MX2021005389A (es) | Formulaciones de nanoparticulas lipidicas. | |
US20220001025A1 (en) | RNA Particles Comprising Polysarcosine | |
Yang et al. | Recent advances in lipid nanoparticles for delivery of mRNA | |
WO2020069718A1 (en) | Rna particles comprising polysarcosine | |
US20230241223A1 (en) | Rna particles comprising polysarcosine | |
Hope | Enhancing siRNA delivery by employing lipid nanoparticles | |
WO2016045732A1 (en) | Stable formulations of lipids and liposomes | |
Pengnam et al. | A novel plier-like gemini cationic niosome for nucleic acid delivery | |
Boloix et al. | Engineering pH‐Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics | |
Anwar et al. | Enhancing the effectiveness of oligonucleotide therapeutics using cell-penetrating peptide conjugation, chemical modification, and carrier-based delivery strategies | |
JP2022543191A (ja) | 増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達 | |
Moshikur et al. | Recent advances in biocompatible ionic liquids in drug formulation and delivery | |
EP4284438A1 (en) | Nucleic acid delivery | |
Goldman et al. | Understanding structure activity relationships of Good HEPES lipids for lipid nanoparticle mRNA vaccine applications | |
AU2006305318B2 (en) | Carrier composition for nucleic acid transport | |
Desai et al. | Nanoadjuvants: promising bioinspired and biomimetic approaches in vaccine innovation | |
US20230099898A1 (en) | Composite rna particles | |
WO2023057935A1 (en) | Lipid nanoparticle comprising a nucleic acid-binding protein | |
WO2024044178A1 (en) | Lipid nanoparticle (lnp) composition or formulation for nucleic acid therapeutics |